ReviewBioactive materials2026
Hydrogel-based tumor embolization and synergistic therapeutic strategies.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- A multifunctional hydrogel dressing for wound healing and in vitro cytotoxicity against breast cancer cells: association with GRP78 expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hydrogel co-delivery of 5-fluorouracil and siRNA attenuates TGF-β1-mediated MMT to prevent postoperative peritoneal metastasis and adhesion in colorectal cancer.Asian journal of pharmaceutical sciences · 2026Article
- Endovascular Embolization in Neurovascular Disease: Material Science, Multimodal Management, and Future Horizons.Biomedicines · 2026Review
- Hydrogel-Based Immunomodulation of Tumor Immune Microenvironment in Hepatocellular Carcinoma: Current Strategies and Future Directions.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogels, characterized by their porous network structures and microenvironment-responsive properties, have been widely explored for tumor embolization. Physically or dynamically crosslinked hydrogels-such as ionic, hydrogen-bonded, or supramolecular systems-exhibit favorable microcatheter injectability and shear-thinning behavior, whereas covalently crosslinked systems are typically delivered as low-viscosity precursors for in situ gelation. These features endow embolic hydrogels with tunable drug delivery capacity and excellent biocompatibility, enabling precise occlusion of tumor-feeding arteries and controlled, localized therapeutic release. This review uniquely emphasizes the innovative design of multifunctional hydrogels, focusing on their role in synergistic multimodal therapies and personalized cancer treatment. It provides a comprehensive overview of the latest advancements in the preparation methods and functional properties of embolic hydrogels, alongside their emerging clinical applications. Additionally, we address the challenges hindering clinical translation and propose future directions, including the personalized design of intelligent hydrogels and the exploration of synergistic mechanisms for multimodal therapeutic strategies. This review offers valuable insights into the design, development, and clinical application of embolic hydrogels for precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.